EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Urinary multi-omics meets artificial intelligence in bladder cancer: from liquid biopsy to clinical decision-making

Tianyi Liu, Heng Xu, Xiaokang Wang, Liyuan Wu, Juan Tang, Zhen Wu, Shengjun Xiao

Frontiers in Genetics · 20.11.2026 · 17

DOI: 10.3389/fgene.2026.2022740 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Genetics, online erschienen am 20.11.2026. Verfasst von Tianyi Liu und 6 weiteren Autor:innen. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bladder cancer is among the most recurrence-prone malignancies, and its management remains anchored to invasive cystoscopy and cytology, which have limited sensitivity. Urine, which is in direct contact with the tumor, carries a rich molecular cargo, including urinary tumor-derived DNA (utDNA), the tumor-derived fraction of urinary cell-free DNA, alongside methylation marks, extracellular vesicle (EV) cargo, and exfoliated cells. These components can now be interrogated through multi-omics profiling and interpreted using artificial intelligence (AI). In this Mini Review, we integrate these layers into a single translational framework: microfluidic “urine-on-chip” technologies convert a drop of urine into standardized, analysis-ready multi-omic data, while machine learning and deep learning models—increasingly governed by STARD-AI/TRIPOD + AI reporting standards—transform these data into diagnostic, prognostic, and treatment-response predictions. We highlight clinically mature anchors, including the utMeMA methylation assay (90.0%/83.1%), the Uromonitor mutation test (TERT/FGFR3/KRAS; 80.2%/96.9%, meta-analysis), chip-based cytometry for detecting high-grade disease, and an externally validated autonomous urine cytology system. These figures are assay-specific and should not be interpreted as platform-wide benchmarks. Finally, we define the priorities—pre-analytical standardization, external validation, and cost-effectiveness—that will advance urinary multi-omic AI from its current performance level into routine practice along a “detect–decide–treat–monitor” digital management pathway.

Zitieren

APA

Liu, T., Xu, H., Wang, X., Wu, L., Tang, J., Wu, Z., & Xiao, S. (2026). Urinary multi-omics meets artificial intelligence in bladder cancer: from liquid biopsy to clinical decision-making. Frontiers in Genetics, 17. https://doi.org/10.3389/fgene.2026.2022740

Vancouver

Liu T, Xu H, Wang X, Wu L, Tang J, Wu Z, et al. Urinary multi-omics meets artificial intelligence in bladder cancer: from liquid biopsy to clinical decision-making. Frontiers in Genetics. 2026;17. doi:10.3389/fgene.2026.2022740

BibTeX
@article{Liu2026,
  author = {Liu, Tianyi and Xu, Heng and Wang, Xiaokang and Wu, Liyuan and Tang, Juan and Wu, Zhen and Xiao, Shengjun},
  title = {Urinary multi-omics meets artificial intelligence in bladder cancer: from liquid biopsy to clinical decision-making},
  journal = {Frontiers in Genetics},
  year = {2026},
  volume = {17},
  doi = {10.3389/fgene.2026.2022740}
}
Kostenlos starten →